Appleton & Oshkosh Clinical Trials available
CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A01105: Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
NRG-GU003: A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer
EAY131: Molecular Analysis for Therapy Choice (MATCH)
NRG-GI004: Metastatic Colorectal Cancer dMMR Immunotherapy Study (COMMIT): A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolimumab or Atezolimumab monotherapy in the First-line treatment of Patients with deficient mismatch repair (dMMR) Metastatic Colorectal Cancer
If interested or want more information about the trials, call the research nurse at the cancer center: 920-831-1245 or email Dale.email@example.com.
Enter from Ninth Avenue, Park in the lot outside of the Mercy Oakwood Medical Building and enter in the Mercy Oakwood Medical Building – covered patient drop-off area is available.
Take the elevator to the 2nd floor, exit the elevator to your left and walk down the hallway to suite 213.